Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 2 Absolute improvement in perfusion defect size at eight weeks post-treatment: Ad5FGF-4 reduced the total and reversible perfusion defect size (RPDS) by 4.6% and 4.2%, respectively (p < 0.001). In the placebo group, the reductions were only 2.4% (p = 0.14) and 1.6% (p = 0.32), respectively. However, the difference between Ad5FGF-4 and placebo was not significantly different. White bars = Ad5FGF-4; black bars = placebo.
|
